HRP20230798T1 - Inhibitori transglutaminaze 2 (tg2) - Google Patents
Inhibitori transglutaminaze 2 (tg2) Download PDFInfo
- Publication number
- HRP20230798T1 HRP20230798T1 HRP20230798TT HRP20230798T HRP20230798T1 HR P20230798 T1 HRP20230798 T1 HR P20230798T1 HR P20230798T T HRP20230798T T HR P20230798TT HR P20230798 T HRP20230798 T HR P20230798T HR P20230798 T1 HRP20230798 T1 HR P20230798T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- pharmaceutically acceptable
- disease
- acceptable salt
- fibrosis
- Prior art date
Links
- 108700039882 Protein Glutamine gamma Glutamyltransferase 2 Proteins 0.000 title claims 2
- 102100038095 Protein-glutamine gamma-glutamyltransferase 2 Human genes 0.000 title claims 2
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 208000015943 Coeliac disease Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- OBSSBNOYCXOADJ-MYHKYFONSA-N methyl N-[(E,2S)-7-(dimethylamino)-1-[[1-[[4-(2-methylpropyl)-1H-benzimidazol-2-yl]methyl]-2-oxopyridin-3-yl]amino]-1,7-dioxohept-5-en-2-yl]carbamate Chemical compound CN(C(/C=C/CC[C@@H](C(NC=1C(N(C=CC=1)CC1=NC2=C(N1)C=CC=C2CC(C)C)=O)=O)NC(OC)=O)=O)C OBSSBNOYCXOADJ-MYHKYFONSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
Claims (11)
1. Spoj koji je metil N-[(E,1S)-6-(dimetilamino)-1-[[1-[(4-izobutil-1H-benzimidazol-2-il)metil]-2-okso-3-piridil]karbamoil]-6-okso-heks-4-enil]karbamat
[image]
ili njegova farmaceutski prihvatljiva sol.
2. Spoj prema zahtjevu 1 koji je
[image]
3. Spoj prema zahtjevu 1 koji je farmaceutski prihvatljiva sol od
[image]
4. Farmaceutski pripravak koji sadrži spoj ili njegovu farmaceutski prihvatljivu sol prema bilo kojem od zahtjeva 1-3 i farmaceutski prihvatljivu pomoćnu tvar.
5. Spoj ili njegova farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 1-3 za uporabu u terapiji.
6. Spoj ili njegova farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 1-3 ili farmaceutski pripravak prema zahtjevu 4 za uporabu u liječenju bolesti ili poremećaja posredovanih transglutaminazom 2.
7. Spoj ili njegova farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 1-3 ili farmaceutski pripravak prema zahtjevu 4 za uporabu u liječenju celijakije, neurodegenerativne bolesti, očne bolesti, raka, ili fibroze.
8. Spoj ili farmaceutski pripravak za uporabu prema zahtjevu 7, naznačen time što je očna bolest odabrana između makularne degeneracije, glaukoma, katarakte, i uveitisa.
9. Spoj ili farmaceutski pripravak za uporabu prema zahtjevu 7, naznačen time što je neurodegenerativna bolest odabrana između Parkinsonove bolesti, Huntingtonove bolesti, i Alzheimerove bolesti.
10. Spoj ili farmaceutski pripravak za uporabu prema zahtjevu 7, naznačen time što je fibroza odabrana između fibroze bubrega, idiopatske plućne fibroze, i fibroze jetre.
11. Spoj ili farmaceutski prihvatljiva sol prema zahtjevu 1 ili 2 za uporabu u liječenju celijakije.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862717697P | 2018-08-10 | 2018-08-10 | |
US201962845229P | 2019-05-08 | 2019-05-08 | |
PCT/US2019/045827 WO2020033784A1 (en) | 2018-08-10 | 2019-08-09 | Transglutaminase 2 (tg2) inhibitors |
EP19846381.2A EP3833348B1 (en) | 2018-08-10 | 2019-08-09 | Transglutaminase 2 (tg2) inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20230798T1 true HRP20230798T1 (hr) | 2023-10-27 |
Family
ID=69415167
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20230798TT HRP20230798T1 (hr) | 2018-08-10 | 2019-08-09 | Inhibitori transglutaminaze 2 (tg2) |
Country Status (28)
Country | Link |
---|---|
US (2) | US20210163480A1 (hr) |
EP (2) | EP4219460A1 (hr) |
JP (1) | JP7433315B2 (hr) |
KR (1) | KR20210044248A (hr) |
CN (1) | CN112789040A (hr) |
AU (1) | AU2019318543B2 (hr) |
BR (1) | BR112021002532A2 (hr) |
CA (1) | CA3109195A1 (hr) |
CL (1) | CL2021000328A1 (hr) |
CO (1) | CO2021001472A2 (hr) |
CY (1) | CY1126147T1 (hr) |
DK (1) | DK3833348T3 (hr) |
ES (1) | ES2947438T3 (hr) |
FI (1) | FI3833348T3 (hr) |
HR (1) | HRP20230798T1 (hr) |
HU (1) | HUE062140T2 (hr) |
IL (1) | IL280719B2 (hr) |
LT (1) | LT3833348T (hr) |
MX (1) | MX2021001550A (hr) |
PH (1) | PH12021500008A1 (hr) |
PL (1) | PL3833348T3 (hr) |
PT (1) | PT3833348T (hr) |
RS (1) | RS64464B1 (hr) |
SG (1) | SG11202100736PA (hr) |
SI (1) | SI3833348T1 (hr) |
TW (1) | TWI825144B (hr) |
UY (1) | UY38333A (hr) |
WO (1) | WO2020033784A1 (hr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11466017B2 (en) | 2011-03-10 | 2022-10-11 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
CN109475531B (zh) | 2016-05-31 | 2021-08-17 | 得克萨斯州立大学董事会 | Ptpn11的杂环抑制剂 |
SG11202010822SA (en) | 2018-05-02 | 2020-11-27 | Navire Pharma Inc | Substituted heterocyclic inhibitors of ptpn11 |
SG11202100199UA (en) | 2018-08-10 | 2021-02-25 | Navire Pharma Inc | 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer |
TWI825144B (zh) * | 2018-08-10 | 2023-12-11 | 美商思達利醫藥公司 | 第二型轉麩醯胺酸酶(tg2)抑制劑 |
KR20240035404A (ko) * | 2021-06-30 | 2024-03-15 | 제디라 게엠베하 | 트랜스글루타미나제 억제제 |
WO2023090479A1 (ko) * | 2021-11-18 | 2023-05-25 | 주식회사 엠디바이오팜 | 신규한 트랜스글루타미나제 2 억제제 및 이의 용도 |
CN115611760A (zh) * | 2022-10-13 | 2023-01-17 | 天津药明康德新药开发有限公司 | 一种适合规模化生产(s)-2-氨基-5-炔基己酸的化学合成方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
GB9509271D0 (en) | 1995-05-05 | 1995-06-28 | Biopharm Res & Dev Ltd | Blood clot stabilisation inhibitors |
US7579313B2 (en) | 2003-11-18 | 2009-08-25 | The Board Of Trustees Of The Leland Stanford Junior University | Transglutaminase inhibitors and methods of use thereof |
DE102006052755A1 (de) | 2006-11-08 | 2008-05-15 | N-Zyme Biotec Gmbh | Michaelsysteme als Transglutaminaseinhibitoren |
WO2012078519A2 (en) * | 2010-12-06 | 2012-06-14 | Numerate, Inc. | 3-acylidene-2-oxoindole derivatives for inhibition of transglutaminase 2 |
US8889716B2 (en) * | 2011-05-10 | 2014-11-18 | Chdi Foundation, Inc. | Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof |
CN104136431B (zh) * | 2011-12-21 | 2017-03-15 | 小野药品工业株式会社 | 作为凝血因子XIa抑制剂的吡啶酮和嘧啶酮衍生物 |
EP2687511A1 (de) * | 2012-07-17 | 2014-01-22 | Zedira GmbH | Pyridinonderivate als Gewebetransglutaminaseinhibitoren |
KR101548789B1 (ko) | 2012-12-21 | 2015-09-01 | 주식회사 엘지화학 | 케이블형 이차전지 및 이의 제조 방법 |
EP3342779A1 (en) | 2016-12-27 | 2018-07-04 | Zedira GmbH | Inhibitors of transglutaminases |
TWI825144B (zh) * | 2018-08-10 | 2023-12-11 | 美商思達利醫藥公司 | 第二型轉麩醯胺酸酶(tg2)抑制劑 |
-
2019
- 2019-08-08 TW TW108128272A patent/TWI825144B/zh active
- 2019-08-09 FI FIEP19846381.2T patent/FI3833348T3/fi active
- 2019-08-09 UY UY0001038333A patent/UY38333A/es unknown
- 2019-08-09 CA CA3109195A patent/CA3109195A1/en active Pending
- 2019-08-09 HR HRP20230798TT patent/HRP20230798T1/hr unknown
- 2019-08-09 BR BR112021002532-4A patent/BR112021002532A2/pt unknown
- 2019-08-09 WO PCT/US2019/045827 patent/WO2020033784A1/en active Application Filing
- 2019-08-09 SI SI201930559T patent/SI3833348T1/sl unknown
- 2019-08-09 EP EP23174889.8A patent/EP4219460A1/en active Pending
- 2019-08-09 MX MX2021001550A patent/MX2021001550A/es unknown
- 2019-08-09 KR KR1020217006925A patent/KR20210044248A/ko unknown
- 2019-08-09 PT PT198463812T patent/PT3833348T/pt unknown
- 2019-08-09 AU AU2019318543A patent/AU2019318543B2/en active Active
- 2019-08-09 HU HUE19846381A patent/HUE062140T2/hu unknown
- 2019-08-09 CN CN201980065467.5A patent/CN112789040A/zh active Pending
- 2019-08-09 EP EP19846381.2A patent/EP3833348B1/en active Active
- 2019-08-09 US US17/267,110 patent/US20210163480A1/en active Pending
- 2019-08-09 JP JP2021531468A patent/JP7433315B2/ja active Active
- 2019-08-09 SG SG11202100736PA patent/SG11202100736PA/en unknown
- 2019-08-09 PL PL19846381.2T patent/PL3833348T3/pl unknown
- 2019-08-09 RS RS20230613A patent/RS64464B1/sr unknown
- 2019-08-09 DK DK19846381.2T patent/DK3833348T3/da active
- 2019-08-09 LT LTEPPCT/US2019/045827T patent/LT3833348T/lt unknown
- 2019-08-09 ES ES19846381T patent/ES2947438T3/es active Active
- 2019-08-09 IL IL280719A patent/IL280719B2/en unknown
-
2021
- 2021-01-27 PH PH12021500008A patent/PH12021500008A1/en unknown
- 2021-02-08 CL CL2021000328A patent/CL2021000328A1/es unknown
- 2021-02-09 CO CONC2021/0001472A patent/CO2021001472A2/es unknown
-
2022
- 2022-05-20 US US17/749,335 patent/US11548892B1/en active Active
-
2023
- 2023-08-04 CY CY20231100392T patent/CY1126147T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20230798T1 (hr) | Inhibitori transglutaminaze 2 (tg2) | |
HRP20201304T1 (hr) | Spoj derivata 1,3,4-oksadiazol-amida koji služi kao inhibitor histonske deacetilaze 6 i farmaceutski pripravak koji sadrži taj spoj | |
EA201892395A1 (ru) | Лекарственные составы ингибитора lsd1 | |
PH12015501942A1 (en) | Susbtituted 3-phenylpropylamine derivatives for the treatment of opthalmic diseases and disorders | |
MX2016014634A (es) | Compuestos para el tratamiento de enfermedades y trastornos oftalmicos. | |
HRP20160135T1 (hr) | Derivati 2-(2,4,5-supstituiranog-anilino) pirimidina kao modulatori egfr koji su korisni za lijeäśenje raka | |
JP2018506570A5 (hr) | ||
PH12016501310A1 (en) | Pharmaceutical compositions comprising azd9291 | |
WO2016164675A8 (en) | Substituted quinazoline compounds and methods of use thereof | |
JP2017222722A5 (hr) | ||
PH12015501208A1 (en) | Amine derivative compounds for treating ophthalmic diseases and disorders | |
MX2018004364A (es) | Acidos pirazolo [3,4-b] piridin-6-carboxilicos sustituidos y su uso. | |
MX2021014115A (es) | Derivados de aminoquinazolina como inhibidores del purinoreceptor 3 de p2x (p2x3). | |
MX2017013483A (es) | Compuestos y su uso como inhibidores de ?-secretasa 1 (bace1). | |
WO2017070647A8 (en) | Nicotinamide for use in the treatment and prevention of ocular neurodegenerative disorder (e.g. glaucoma) | |
WO2018033792A3 (en) | Ophthalmic pharmaceutical compositions and uses relating thereto | |
CL2020003101A1 (es) | Sales de sepiapterina farmacéuticamente aceptables. | |
JOP20220105A1 (ar) | مجموعات سلفون أميد أمينو أريل غير متجانس بها 5 ذرات لعلاج حالات يتوسط في حدوثها نشاط cftr | |
JP2016027060A5 (hr) | ||
CO2022007946A2 (es) | Heteroarilaminosulfonamidas de 6 miembros para tratar enfermedades y afecciones mediadas por la actividad de cftr deficiente | |
JP2013523846A5 (hr) | ||
JP2017530983A5 (hr) | ||
WO2010028088A3 (en) | Sulfur-linked compounds for treating opthalmic diseases and disorders | |
JOP20210185A1 (ar) | مركبات هالو-آلِّيلامين واستخدامها | |
BR112017011623A2 (pt) | composições farmacêuticas e processo para a preparação de uma composição |